Form 4: TOI Director Anne McGeorge Boosts Stock Holdings

The Oncology Institute Director Anne McGeorge acquired 108,024 shares of common stock through restricted stock unit grants.

Summary

• Anne McGeorge, a Director of The Oncology Institute, Inc. (TOI), reported an acquisition of common stock.
• On November 20, 2025, McGeorge acquired 67,901 shares of common stock in the form of restricted stock units (RSUs).
• These 67,901 RSUs are scheduled to vest in full on the Issuer's 2026 annual stockholder meeting date, contingent upon her continued service with the Issuer.
• Additionally, on November 20, 2025, McGeorge acquired another 40,123 shares of common stock, also in the form of restricted stock units, which were fully vested upon grant.
• The acquisition price for both grants was $0 per share.
• Following these transactions, Anne McGeorge beneficially owns a total of 291,370 shares of The Oncology Institute, Inc. common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine insider equity grant, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. No significant negative or highly positive operational news is present.

Positives

• Increased insider ownership, even through grants, can signal alignment of management and director interests with shareholders.
• The grant of fully vested restricted stock units immediately increases the director's direct stake in the company.

Risks

• The vesting of 67,901 restricted stock units is subject to Anne McGeorge's continued service with the Issuer through the 2026 annual stockholder meeting date, meaning these shares are not guaranteed if service ceases.

Future Outlook

A portion of the acquired restricted stock units (67,901 shares) are scheduled to vest in 2026, contingent on the director's continued service, indicating future equity ownership changes.

Industry Context

Insider transaction disclosures like this Form 4 are routine regulatory filings that provide transparency into how company directors and officers are compensated and manage their equity stakes. Such grants are a common form of executive and director compensation in the healthcare services industry, aiming to align long-term interests.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it aligns the director's financial interests with the company's performance.
• Employees: The director's continued service, a condition for vesting, implies stability in leadership.

Next Steps

• The 67,901 restricted stock units will vest on the Issuer's 2026 annual stockholder meeting date, subject to continued service.

Key Dates

Keywords

The Oncology Institute, TOI, Anne McGeorge, Director, Insider Trading, Form 4, Restricted Stock Units, RSU Grant, Beneficial Ownership, Equity Compensation